Distinct COVID-19 vaccine combinations result in divergent immune responses
暂无分享,去创建一个
D. Baarle | M. Koopmans | N. Kootstra | W. Rietdijk | B. Haagmans | A. Huckriede | A. Goorhuis | C. Geurtsvankessel | L. Visser | D. Postma | S. Bogers | M. Lafeber | V. Dalm | R. D. Vries | L. Gommers | P. Kuy | D. Geers | R. Sablerolles | L. Zaeck | Sharona Rugebregt | Ngoc H. Tan | L. V. Dijk | Leanne P.M. van Leeuwen | -. S. R. Group
[1] D. Montefiori,et al. Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19 , 2023, Nature communications.
[2] Henrik Nielsen,et al. Omicron Variant-Specific Serological Imprinting Following BA.1 or BA.4/5 Bivalent Vaccination and Previous SARS-CoV-2 Infection: A Cohort Study , 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] William F. Fadel,et al. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023 , 2023, MMWR. Morbidity and mortality weekly report.
[4] V. Simon,et al. Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies , 2023, The Lancet Microbe.
[5] Z. Moore,et al. Durability of Bivalent Boosters against Omicron Subvariants , 2023, The New England journal of medicine.
[6] C. Geurtsvankessel,et al. COVID-19 vaccine effectiveness and evolving variants: understanding the immunological footprint , 2023, The Lancet Respiratory Medicine.
[7] M. Davenport,et al. Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis , 2023, Nature Communications.
[8] K. Joyal-Desmarais,et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022 , 2023, The Lancet Respiratory Medicine.
[9] Xiangxi Wang,et al. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5 , 2023, The Lancet Infectious Diseases.
[10] Stephen J. Thomas,et al. Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years , 2023, The New England journal of medicine.
[11] P. Bieniasz,et al. Molecular fate-mapping of serum antibody responses to repeat immunization , 2023, Nature.
[12] D. Barouch,et al. Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters , 2023, The New England journal of medicine.
[13] M. Koopmans,et al. Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1 , 2023, The Lancet Microbe.
[14] Xuping Xie,et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster , 2022, Nature Medicine.
[15] A. Gordon,et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants , 2022, Cell.
[16] M. Diamond,et al. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans , 2022, bioRxiv.
[17] D. Montefiori,et al. A Bivalent Omicron-Containing Booster Vaccine against Covid-19 , 2022, The New England journal of medicine.
[18] M. Davenport,et al. Predicting the efficacy of variant-modified COVID-19 vaccine boosters , 2022, Nature Medicine.
[19] M. Koopmans,et al. Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct , 2022, Science Immunology.
[20] O. Watson,et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study , 2022, The Lancet Infectious Diseases.
[21] M. Koopmans,et al. Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients , 2022, Science Immunology.
[22] D. Montefiori,et al. Homologous and Heterologous Covid-19 Booster Vaccinations , 2022, The New England journal of medicine.
[23] M. Koopmans,et al. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming , 2022, The New England journal of medicine.
[24] C. von Kalle,et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study , 2021, The Lancet Respiratory Medicine.
[25] Vaccine boosters , 2018, Nature.
[26] D. Chitwood,et al. Cc-by-nc-nd 4.0 International License , 2022 .